Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Experimental & Molecular Medicine ; : 607-616, 2008.
Article Dans Anglais | WPRIM | ID: wpr-59827

Résumé

Lysophosphatidic acid (LPA) is a bioactive phospholipids and involves in various cellular events, including tumor cell migration. In the present study, we investigated LPA receptor and its transactivation to EGFR for cyclooxygenase-2 (COX-2) expression and cell migration in CAOV-3 ovarian cancer cells. LPA induced COX-2 expression in a dose-dependent manner, and pretreatment of the cells with pharmacological inhibitors of Gi (pertussis toxin), Src (PP2), EGF receptor (EGFR) (AG1478), ERK (PD98059) significantly inhibited LPA- induced COX-2 expression. Consistent to these results, transfection of the cells with selective Src siRNA attenuated COX-2 expression by LPA. LPA stimulated CAOV-3 cell migration that was abrogated by pharmacological inhibitors and antibody of EP2. Higher expression of LPA2 mRNA was observed in CAOV-3 cells, and transfection of the cells with a selective LPA2 siRNA significantly inhibited LPA-induced activation of EGFR and ERK, as well as COX-2 expression. Importantly, LPA2 siRNA also blocked LPA-induced ovarian cancer cell migration. Collectively, our results clearly show the significance of LPA2 and Gi/Src pathway for LPA-induced COX-2 expression and cell migration that could be a promising drug target for ovarian cancer cell metastasis.


Sujets)
Femelle , Humains , Butadiènes/pharmacologie , Lignée cellulaire tumorale , Mouvement cellulaire/effets des médicaments et des substances chimiques , Cyclooxygenase 2/biosynthèse , Extracellular Signal-Regulated MAP Kinases/antagonistes et inhibiteurs , Flavonoïdes/pharmacologie , Sous-unités alpha Gi-Go des protéines G/antagonistes et inhibiteurs , Lysophospholipides/pharmacologie , Nitriles/pharmacologie , Tumeurs de l'ovaire/métabolisme , Toxine pertussique/pharmacologie , Protein-tyrosine kinases/antagonistes et inhibiteurs , Protéines proto-oncogènes/antagonistes et inhibiteurs , Pyrimidines/pharmacologie , Récepteurs ErbB/antagonistes et inhibiteurs , Récepteurs à l'acide phosphatidique/métabolisme , Récepteur prostaglandine E/métabolisme , Transduction du signal , Activation de la transcription , Tyrphostines/pharmacologie
SÉLECTION CITATIONS
Détails de la recherche